Safety and Tolerability of TAR-200 mg in Subjects With Non-Muscle-Invasive Bladder Cancer

A Phase 1b, Multicenter, Open Label Study Evaluating Safety, Tolerability and Preliminary Efficacy of GemRIS 225 mg in Subjects With Non-Muscle-Invasive Urothelial Carcinoma of the Bladder

The purpose of this study is to determine if TAR-200, an investigational drug-delivery system is safe and tolerable in patients with recurrent low or intermediate risk non-muscle-invasive bladder cancer (NMIBC) between diagnosis and transurethral resection of bladder tumors (TURBT)

Study Overview

• Status: Completed
• Conditions: Urinary Bladder Cancer
• Intervention / Treatment: Drug: Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200

• Study Type: Interventional
• Enrollment (Actual): 12
• Phase: Phase 1

Contacts and Locations

Study Locations

• Netherlands
  • Nijmegen, Netherlands
    • Radboudumc
  • Nijmegen, Netherlands
    • Canisius Wilhelmina Ziekenhuis

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 16 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• A documented history of histologically-confirmed low or intermediate risk urothelial carcinoma of the bladder, excluding carcinoma in situ (pTis), pathologic stage pT1 (invasive into lamina propria) and high-Grade disease, judged not to be muscle infiltrating (pT2 or greater) and accessible for resection.
• Adequate laboratory parameters.
• Screening urinalysis showing no clinically significant abnormalities except those attributable to bladder cancer.
• Not undergoing active treatment in last 3 months for prior or concurrent neoplastic disease and have fully recovered from treatment effects. Patients undergoing concurrent hormonal therapy treatment for prostate cancer will be allowed to enroll.

Exclusion Criteria:

• Exposure to BCG therapy and/or any other intravesical. chemotherapeutic agent less than 1 year prior to enrollment, except single postoperative instillations.
• Absence of visible tumor at Screening.
• Any previous exposure to intravesical gemcitabine instillations within the past 12 months.
• Presence of any bladder or urethral anatomical feature that in the opinion of the investigator may prevent the safe placement, indwelling use or removal of TAR-200 (i.e. bladder diverticula, complete incontinence).
• Patients with a high-Grade urine cytology at recurrence.
• Currently receiving other systemic or intravesical chemotherapy.
• Pelvic radiotherapy administered within 6 months prior to enrollment. Patients who received radiotherapy ≥ 6 months prior to enrollment must demonstrate no cystoscopic evidence or clinical symptoms of radiation cystitis.
• Bladder Post-Void Residual Volume (PVR) of > 250-mL.
• Active, uncontrolled urogenital bacterial, viral, or fungal infections, including urinary tract infection. Skin/nail fungal infections are not exclusionary. Subjects with active shingles (varicella zoster infection) will be excluded from the study.
• History or presence of any significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, gynecological, endocrine, immunological, dermatological, neurological or psychiatric disease or disorder that, in the opinion of the investigator, contraindicates participation.
• Concomitant immunosuppressive medications, such as methotrexate or TNF inhibitors, within 2 weeks of Study Day 0, exclusive of steroid doses ≤5 mg daily.
• Female subject who is pregnant (as verified by urine test at time of screening) or lactating, or of childbearing potential and not using acceptable methods of contraception.
• Unwilling or unable to provide informed consent or comply with the requirements of this protocol, including the presence of any condition (physical, mental or social) that is likely to affect the subject's return for scheduled visits and follow-up.
• Other unspecified reasons that, in the opinion of the investigator or TARIS, make the patient unsuitable for enrollment.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Sequential Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: 7-Day Regimen; TAR-200 is placed into the bladder through an inserter on Study Day 0 and is removed on Study Day 7. TAR-200 releases gemcitabine gradually during the 7 day indwelling time. A second TAR-200 is placed in the bladder on Study Day 21 and is removed on Study Day 28, which is the day of the TURBT.	Drug: Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200; TAR-200 is a passive, nonresorbable gemcitabine-releasing intravesical system whose primary mode of action is the controlled release of gemcitabine into the bladder over an indwelling period.
Experimental: 21-Day Regimen; TAR-200 is placed into the bladder through an inserter on Study Day 0 and is removed on Study Day 21. TAR-200 releases gemcitabine gradually during the 21 day indwelling time. A second TAR-200 is placed in the bladder on Study Day 21 and is removed on Study Day 42.	Drug: Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200; TAR-200 is a passive, nonresorbable gemcitabine-releasing intravesical system whose primary mode of action is the controlled release of gemcitabine into the bladder over an indwelling period.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Safety as defined by the number of participants with treatment emergent adverse events (TEAEs) coded with MedDRA and graded for severity with CTCAE v4.0	From the point of signing the informed consent form through last study visit, up to 59 days.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of participants who are tolerant of TAR-200 indwelling (Arm 1)		From Day 0 up to Day 7
Percentage of participants who are tolerant of TAR-200 indwelling (Arm 1)		From Day 0 up to Day 7
Number of participants who are tolerant of TAR-200 indwelling (Arm 1)		From Day 21 up to Day 28
Percentage of participants who are tolerant of TAR-200 indwelling (Arm 1)		From Day 21 up to Day 28
Cmax, plasma dFdU (Arm 1)	Analysis of Cmax (maximum concentration achieved over time) of diflourodeoxyuridine (dFdU) in plasma.	From Day 0 up to Day 32
Tmax, plasma dFdU (Arm 1)	Analysis of Tmax (Day at which maximum concentration was achieved) of diflourodeoxyuridine (dFdU) in plasma.	From Day 0 up to Day 32
Cavg, plasma dFdU (Arm 1)	Analysis of Descriptive statistics (e.g. sample size, mean and median, quartiles, minimum and maximum and box plots) of the concentration of diflourodeoxyuridine (dFdU) in plasma.	From Day 0 up to Day 32
Cmax, plasma dFdC (Arm 1)	Analysis of Cmax (maximum concentration achieved over time) of gemcitabine (deoxydifluorocytidine hydrochloride - dFdC) in plasma.	From Day 0 up to Day 32
Tmax, plasma dFdC (Arm 1)	Analysis of Tmax (Day at which maximum concentration was achieved) of gemcitabine (deoxydifluorocytidine hydrochloride - dFdC) in plasma	From Day 0 up to Day 32
Cavg, plasma dFdC (Arm 1)	Analysis of Descriptive statistics (e.g. sample size, mean and median, quartiles, minimum and maximum and box plots) of the concentration of gemcitabine (deoxydifluorocytidine hydrochloride - dFdC) in plasma.	From Day 0 up to Day 32
Cmax, urine dFdU (Arm 1)	Analysis of Cmax (maximum concentration achieved over time) of diflourodeoxyuridine (dFdU) in urine.	From Day 0 up to Day 32
Tmax, urine dFdU (Arm 1)	Analysis of Tmax (Day at which maximum concentration was achieved) of diflourodeoxyuridine (dFdU) in urine	From Day 0 up to Day 32
Cavg, urine dFdU (Arm 1)	Analysis of Descriptive statistics (e.g. sample size, mean and median, quartiles, minimum and maximum and box plots) of the concentration of diflourodeoxyuridine (dFdU) in urine.	From Day 0 up to Day 32
Cmax, urine dFdC (Arm 1)	Analysis of Cmax (maximum concentration achieved over time) of gemcitabine (deoxydifluorocytidine hydrochloride - dFdC) in urine.	From Day 0 up to Day 32
Tmax, urine dFdC (Arm 1)	Analysis of Tmax (Day at which maximum concentration was achieved) of gemcitabine (deoxydifluorocytidine hydrochloride - dFdC) in urine.	From Day 0 up to Day 32
Cavg, urine dFdC (Arm 1)	Analysis of Descriptive statistics (e.g. sample size, mean and median, quartiles, minimum and maximum and box plots) of the concentration of gemcitabine (deoxydifluorocytidine hydrochloride - dFdC) in urine	From Day 0 up to Day 32
Preliminary anti-tumor effects will be assessed in tumor material (post-treatment) for assessment of immunohistochemical tissue biomarkers of drug-induced cell death (AKT, CD31, Ki67, TUNEL). (Arm 1)		Anti-tumor analysis will occur at the following study day visit Day 28
Number of participants who are tolerant of TAR-200 indwelling (Arm 2)		From Day 0 up to Day 21
Percentage of participants who are tolerant of TAR-200 indwelling (Arm 2)		From Day 0 up to Day 21
Number of participants who are tolerant of TAR-200 indwelling (Arm 2)		From Day 21 up to Day 42
Percentage of participants who are tolerant of TAR-200 indwelling (Arm 2)		From Day 21 up to Day 42
Cmax, plasma dFdU (Arm 2)	Analysis of Cmax (maximum concentration achieved over time) of diflourodeoxyuridine (dFdU) in plasma.	From Day 0 up to Day 47
Tmax, plasma dFdU (Arm 2)	Analysis of Tmax (Day at which maximum concentration was achieved) of diflourodeoxyuridine (dFdU) in plasma.	From Day 0 up to Day 47
Cavg, plasma dFdU (Arm 2)	Analysis of Descriptive statistics (e.g. sample size, mean and median, quartiles, minimum and maximum and box plots) of the concentration of diflourodeoxyuridine (dFdU) in plasma.	From Day 0 up to Day 47
Cmax, plasma dFdC (Arm 2)	Analysis of Cmax (maximum concentration achieved over time) of gemcitabine (deoxydifluorocytidine hydrochloride - dFdC) in plasma.	From Day 0 up to Day 47
Tmax, plasma dFdC (Arm 2)	Analysis of Tmax (Day at which maximum concentration was achieved) of gemcitabine (deoxydifluorocytidine hydrochloride - dFdC) in plasma	From Day 0 up to Day 47
Cavg, plasma dFdC (Arm 2)	Analysis of Descriptive statistics (e.g. sample size, mean and median, quartiles, minimum and maximum and box plots) of the concentration of gemcitabine (deoxydifluorocytidine hydrochloride - dFdC) in plasma.	From Day 0 up to Day 47
Cmax, urine dFdU (Arm 2)	Analysis of Cmax (maximum concentration achieved over time) of diflourodeoxyuridine (dFdU) in urine.	From Day 0 up to Day 47
Tmax, urine dFdU (Arm 2)	Analysis of Tmax (Day at which maximum concentration was achieved) of diflourodeoxyuridine (dFdU) in urine	From Day 0 up to Day 47
Cavg, urine dFdU (Arm 2)	Analysis of Descriptive statistics (e.g. sample size, mean and median, quartiles, minimum and maximum and box plots) of the concentration of diflourodeoxyuridine (dFdU) in urine.	From Day 0 up to Day 47
Cmax, urine dFdC (Arm 2)	Analysis of Cmax (maximum concentration achieved over time) of gemcitabine (deoxydifluorocytidine hydrochloride - dFdC) in urine.	From Day 0 up to Day 47
Tmax, urine dFdC (Arm 2)	Analysis of Tmax (Day at which maximum concentration was achieved) of gemcitabine (deoxydifluorocytidine hydrochloride - dFdC) in urine.	From Day 0 up to Day 47
Cavg, urine dFdC (Arm 2)	Analysis of Descriptive statistics (e.g. sample size, mean and median, quartiles, minimum and maximum and box plots) of the concentration of gemcitabine (deoxydifluorocytidine hydrochloride - dFdC) in urine	From Day 0 up to Day 47
Preliminary anti-tumor effects will be assessed in tumor material (post-treatment) for assessment of immunohistochemical tissue biomarkers of drug-induced cell death (AKT, CD31, Ki67, TUNEL). (Arm 2)		Anti-tumor analysis will occur at the following study day visit Day 42

Collaborators and Investigators

• Sponsor: Taris Biomedical LLC
• Investigators: Principal Investigator: Johannes Witjes, MD, Radboud University Medical Center

Study record dates

Study Major Dates

• Study Start (Actual): January 1, 2016
• Primary Completion (Actual): January 1, 2018
• Study Completion (Actual): March 1, 2020

Study Registration Dates

• First Submitted: February 25, 2016
• First Submitted That Met QC Criteria: March 21, 2016
• First Posted (Estimate): March 25, 2016

Study Record Updates

• Last Update Posted (Actual): March 10, 2020
• Last Update Submitted That Met QC Criteria: March 9, 2020
• Last Verified: March 1, 2020

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms; Urologic Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Urologic Diseases; Urinary Bladder Diseases; Urinary Bladder Neoplasms; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Anti-Infective Agents; Antiviral Agents; Enzyme Inhibitors; Antimetabolites, Antineoplastic; Antimetabolites; Antineoplastic Agents; Immunosuppressive Agents; Immunologic Factors; Gemcitabine
• Other Study ID Numbers: TAR-200-102; 2016-000099-66 (EudraCT Number)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No